Juvenile
myelomonocytic leukemia is a rare disease that occurs mostly in the
children who are under four years of age. The abnormal growth of the monocytes
results in the accumulation of monocytes in the bone marrow. This leads to
improper functioning of the bone marrow.
The actual cause of juvenile myelomonocytic leukemia is
still unknown; however, mutation in the RAS gene is observed in patients with
the disease. Fatigue, weakness, dry cough, pallor, and fever are major symptoms
of the medical condition.
Request to Get the Sample Pages at:
The University of Minnesota is in the process of developing
stem cell therapy for the treatment of juvenile myelomonocytic leukemia.
Celgene Corporation is also developing azacytidine, a DNA methylation
inhibitor, for the treatment of this medical condition.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
No comments:
Post a Comment